New research reveals that people who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle plans.
Research printed in a major health publication points out that while obese individuals frequently drop substantial amounts of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying such drugs should be aware of the risk of rapid rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a return to pre-treatment mass in about 18 months.
Analyzing Therapies
The study, which looked at dozens of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who lose weight through lifestyle changes alone generally experience a slower creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Experts suggest the way of the jabs accounts for the accelerated rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means appetite is no longer kept in check, making overeating much more probable."
A Lifelong Disease?
The NHS suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the treatment should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who note that the results "emphasize the long-term nature of obesity," similar to managing conditions like high blood pressure.
User Testimonies
Users who have stopped the jabs report a intense return of cravings.
"I experienced something activating and I was suddenly starving," described an individual.
This difficulty is worsened if users have not adopted lasting dietary or behavioural changes during therapy.
Growing Interest
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is more common among women than males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, researchers stress that while the jabs are potent agents for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated behavioural support.
